335 related articles for article (PubMed ID: 36831248)
1. Targeting Transcription Factors ATF5, CEBPB and CEBPD with Cell-Penetrating Peptides to Treat Brain and Other Cancers.
Greene LA; Zhou Q; Siegelin MD; Angelastro JM
Cells; 2023 Feb; 12(4):. PubMed ID: 36831248
[TBL] [Abstract][Full Text] [Related]
2. Dominant-Negative ATF5 Compromises Cancer Cell Survival by Targeting CEBPB and CEBPD.
Sun X; Jefferson P; Zhou Q; Angelastro JM; Greene LA
Mol Cancer Res; 2020 Feb; 18(2):216-228. PubMed ID: 31676720
[TBL] [Abstract][Full Text] [Related]
3. Cell-Penetrating CEBPB and CEBPD Leucine Zipper Decoys as Broadly Acting Anti-Cancer Agents.
Zhou Q; Sun X; Pasquier N; Jefferson P; Nguyen TTT; Siegelin MD; Angelastro JM; Greene LA
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34065488
[TBL] [Abstract][Full Text] [Related]
4. A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers.
Karpel-Massler G; Horst BA; Shu C; Chau L; Tsujiuchi T; Bruce JN; Canoll P; Greene LA; Angelastro JM; Siegelin MD
Clin Cancer Res; 2016 Sep; 22(18):4698-711. PubMed ID: 27126996
[TBL] [Abstract][Full Text] [Related]
5. Targeting ATF5 in Cancer.
Angelastro JM
Trends Cancer; 2017 Jul; 3(7):471-474. PubMed ID: 28718401
[TBL] [Abstract][Full Text] [Related]
6. The transcription factor ATF5: role in cellular differentiation, stress responses, and cancer.
Sears TK; Angelastro JM
Oncotarget; 2017 Oct; 8(48):84595-84609. PubMed ID: 29137451
[TBL] [Abstract][Full Text] [Related]
7. Dominant-negative ATF5 rapidly depletes survivin in tumor cells.
Sun X; Angelastro JM; Merino D; Zhou Q; Siegelin MD; Greene LA
Cell Death Dis; 2019 Sep; 10(10):709. PubMed ID: 31551409
[TBL] [Abstract][Full Text] [Related]
8. Expression and targeting of transcription factor ATF5 in dog gliomas.
York D; Sproul CD; Chikere N; Dickinson PJ; Angelastro JM
Vet Comp Oncol; 2018 Mar; 16(1):102-107. PubMed ID: 28480569
[TBL] [Abstract][Full Text] [Related]
9. CCAAT/enhancer binding protein alpha, beta and delta gene variants: associations with obesity related phenotypes in the Leeds Family Study.
Bennett CE; Nsengimana J; Bostock JA; Cymbalista C; Futers TS; Knight BL; McCormack LJ; Prasad UK; Riches K; Rolton D; Scarrott T; Barrett JH; Carter AM
Diab Vasc Dis Res; 2010 Jul; 7(3):195-203. PubMed ID: 20460359
[TBL] [Abstract][Full Text] [Related]
10. Mouse chromosomal location of the CCAAT/enhancer binding proteins C/EBP beta (Cebpb), C/EBP delta (Cebpd), and CRP1 (Cebpe).
Jenkins NA; Gilbert DJ; Cho BC; Strobel MC; Williams SC; Copeland NG; Johnson PF
Genomics; 1995 Jul; 28(2):333-6. PubMed ID: 8530045
[TBL] [Abstract][Full Text] [Related]
11. The transcription factor ATF5: role in neurodevelopment and neural tumors.
Greene LA; Lee HY; Angelastro JM
J Neurochem; 2009 Jan; 108(1):11-22. PubMed ID: 19046351
[TBL] [Abstract][Full Text] [Related]
12. Advancements in Activating Transcription Factor 5 Function in Regulating Cell Stress and Survival.
Paerhati P; Liu J; Jin Z; Jakoš T; Zhu S; Qian L; Zhu J; Yuan Y
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806136
[TBL] [Abstract][Full Text] [Related]
13. Dpep Inhibits Cancer Cell Growth and Survival via Shared and Context-Dependent Transcriptome Perturbations.
Zhou Q; Greene LA
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001578
[TBL] [Abstract][Full Text] [Related]
14. p300-dependent acetylation of activating transcription factor 5 enhances C/EBPβ transactivation of C/EBPα during 3T3-L1 differentiation.
Zhao Y; Zhang YD; Zhang YY; Qian SW; Zhang ZC; Li SF; Guo L; Liu Y; Wen B; Lei QY; Tang QQ; Li X
Mol Cell Biol; 2014 Feb; 34(3):315-24. PubMed ID: 24216764
[TBL] [Abstract][Full Text] [Related]
15. Regression/eradication of gliomas in mice by a systemically-deliverable ATF5 dominant-negative peptide.
Cates CC; Arias AD; Nakayama Wong LS; Lamé MW; Sidorov M; Cayanan G; Rowland DJ; Fung J; Karpel-Massler G; Siegelin MD; Greene LA; Angelastro JM
Oncotarget; 2016 Mar; 7(11):12718-30. PubMed ID: 26863637
[TBL] [Abstract][Full Text] [Related]
16. Selective destruction of glioblastoma cells by interference with the activity or expression of ATF5.
Angelastro JM; Canoll PD; Kuo J; Weicker M; Costa A; Bruce JN; Greene LA
Oncogene; 2006 Feb; 25(6):907-16. PubMed ID: 16170340
[TBL] [Abstract][Full Text] [Related]
17. An activating transcription factor 5-mediated survival pathway as a target for cancer therapy?
Sheng Z; Evans SK; Green MR
Oncotarget; 2010 Oct; 1(6):457-460. PubMed ID: 21311102
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of CCAAT/enhancer binding protein-beta and -delta and monocyte chemoattractant protein-1 genes in aortas from hyperinsulinaemic rats.
Sato Y; Nishio Y; Sekine O; Kodama K; Nagai Y; Nakamura T; Maegawa H; Kashiwagi A
Diabetologia; 2007 Feb; 50(2):481-9. PubMed ID: 17180354
[TBL] [Abstract][Full Text] [Related]
19. Anticancer Activity of ST101, A Novel Antagonist of CCAAT/Enhancer Binding Protein β.
Darvishi E; Ghamsari L; Leong SF; Ramirez R; Koester M; Gallagher E; Yu M; Mason JM; Merutka G; Kappel BJ; Rotolo JA
Mol Cancer Ther; 2022 Nov; 21(11):1632-1644. PubMed ID: 36121385
[TBL] [Abstract][Full Text] [Related]
20. Regulated ATF5 loss-of-function in adult mice blocks formation and causes regression/eradication of gliomas.
Arias A; Lamé MW; Santarelli L; Hen R; Greene LA; Angelastro JM
Oncogene; 2012 Feb; 31(6):739-51. PubMed ID: 21725368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
